[]
Galas-Zgorzalewicz B., Kluczyski A., Steinborn B.: Clinical
pharmacokinetics of carbamazepine and valproate in children and
adolescents with epilepsy. Neurol Neurochir Pol 1996; 30 (Suppl. 2):
49–54.
[]
Diaconu C.H., Cuciureanu M., Vlase L., et al.: Food-drug interactions:
grapefruit juice. Rev Med Chir Soc Med Nat Iasi 2011; 115: 245–250.
[]
Potschka H., Fedrowitz M., Lӧscher W.: P-glycoprotein and multidrug
resistance-associated protein are involved in the regulation of
extracellular levels of the major antiepileptic drug carbamazepine in the
brain. Neuroreport 2001; 16: 3557–3560.
[]
Garg S.K., Kumar N., Bhargava V.K., et al.: Effect of grapefruit juice on
carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol
Ther 1998; 64: 286–288.
[]
Bailey D.G., Dresser G.K., Keeft J.H., et al.: Grapefruit-felodipine
interaction: effect of unprocessed fruit and probable active ingredients.
Clin Pharmacol Ther 2000; 68: 468–477.
[]
Dahan A., Altman H.: Food–drug interaction : grapefruit juice augments
drug bioavailability mechanism, extent and relevance. Eur J Clin Nutr
2004; 58: 1–9.
[]
Brunner L.J., Pai K.S., Munar M.Y., et al.: Effect of grapefruit juice on
cyclosporin A pharmacokinetics in pediatric renal transplant patients.
Pediatr Transplant 2000; 4: 313–321.
[]
Hanley M.J., Cerundolo R., Radwanski N, et al.: Grapefruit juice,
lyophilized grapefruit juice, and powdered whole grapefruit inhibit
cytochrome P450-mediated triazolam hydroxylation by beagle dog liver microsomes. J Vet Pharmacol Ther 2010; 33: 189–195.
[]
Lin H.L., Kenaan C., Hollenberg P.F.: Identification of the residue in human
CYP3A4 that is covalently modified by bergamottin and the reactive
intermediate that contributes to the grapefruit juice effect. Drug Metab
Dispos 2012; 40: 998–1006.
[]
Bertilsson L.: Clinical pharmacokinetics of carbamazepine. Clin
Pharmacokinet 1978; 3: 128–143.
[]
Steinborn B.: Znaczenie badań farmakokinetycznych leków
przeciwpadaczkowych w leczeniu padaczki u dzieci i młodzieży. Neurol
Dziec 2006; 15, 29: 7–15.
[]
Tolou-Ghamari Z., Zare M., Habibabadi J.M., et al.: Antiepileptic drugs:
a consideration of clinical and biochemical outcome in patients with
epilepsy. Int J Prev Med 2013; 4 (Suppl. 2): 330–337.
[]
Bailey D.G., Spence J.D., Munoz C., et al.: Interaction of citrus juices with
felodipine and nifedipine. Lancet 1991; 337: 268–269.
[]
Sobaniec W., Kulak W., Strzelecka J., et al.: A comparative study of
vigabatrin vs. carbamazepine in monotherapy of newly diagnosed partial
seizures in children. Pharmacol Rep 2005; 57: 646–653.
[]
Olguin-Reyes S., Camacho-Carranza R., Hernandez-Ojeda S., et al.:
Bergamottin is a competitive inhibitor of CYP1A1 and is antimutagenic
in the Ames test. Food Chem Toxicol 2012; 50: 3094–3099.
[]
He K., Iyer K.R., Hayes R.N., Sinz M.W., Woolf T.F., Hollenberg P.F.:
Inactivation of cytochrome P450 3A4 by bergamottin, a component of
grapefruit juice. Chem Res Toxicol 1998; 11: 252–259.
[]
Schmiedlin-Ren P., Edwards D.J., Fitzsimmons M.E., et al.: Mechanisms
of enhanced oral availability of CYP3A4 substrates by grapefruit
constituents. Decreased enterocyte CYP3A4 concentration and
mechanism-based inactivation by furanocoumarins. Drug Metab Dispos
1997; 25: 1228–1233.
[]
Edwards D.J., Bellevue F.H. 3rd , Woster P.M.: Identification of 6’,7’-
dihydroxy-bergamottin, a cytochrome P450 inhibitor, in grapefruit juice.
Drug Metab Dispos 1996; 24: 1287–1290.
[]
Rodvold K.A., Meyer J.: Drug-food interactions with grapefruit juice.
Infect Med, 1996, 13: 871–873.
[]
Fuhr U., Klittich K., Staib A.H.: Inhibitory effect of grapefruit juice and
its bitter principal, naringenin, on CYP1A2 dependent metabolism of
caffeine in man. Br J Clin Pharmacol 1993; 35: 431–436.
[]
Dresser G.K., Spence J.D., Bailey D.G., et al.: Pharmacokineticpharmacodynamic
consequences and clinical relevance of cytochrome
P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41–57.
[]
Seden K., Dickinson L., Khoo S., et al.: Grapefruite-drug interactions.
Drugs 2010; 70: 2373–2407.
[]
Bailey D.G., Arnold J.M., Spence J.D.: Grapefruit juice and drugs. How
significant is the interaction? Clin Pharmacokinet 1994; 26: 91–98.
Scholar Google
PubMed